|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-09
|
$1,119,110
|
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
$114,308
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221704-01A1
|
$1,050,067
|
$73,505
|
OGUNWOBI, OLORUNSEUN
|
HUNTER COLLEGE
|
|
(ACCSIS) Accelerating Colorectal Cancer Screening through Implementation Science in Appalachia
|
1UG3CA233282-01
|
$770,562
|
$770,562
|
DIGNAN, MARK
|
UNIVERSITY OF KENTUCKY
|
|
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
|
1R01CA231291-01
|
$533,211
|
|
WELLSTEIN, ANTON
|
GEORGETOWN UNIVERSITY
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
5R01CA208535-03
|
$506,533
|
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy
|
5R01CA219866-02
|
$465,400
|
|
DIANTONIO, AARON
|
WASHINGTON UNIVERSITY
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
$501,220
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-03
|
$356,850
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ1) Molecular circuit of multi-ciliogenesis regulates choroid plexus differentiation and tumor development
|
5R01CA220551-03
|
$315,193
|
|
ZHAO, HAOTIAN
|
NEW YORK INST OF TECHNOLOGY
|
|
(PQ1) Progenitor cell malfunction, mutations and changes in microenvironment: A dynamic risk spectrum for cancer evolution
|
5R01CA219893-02
|
$427,989
|
|
GHOSH, MOUMITA
|
NATIONAL JEWISH HEALTH
|
|
(PQ1) The role of cell-to-cell variation in the penetrance of heritable mutant RAS hypodermal neoplasias
|
1R01CA219460-01A1
|
$397,573
|
|
MENDENHALL, ALEXANDER
|
UNIVERSITY OF WASHINGTON
|
|
(PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes
|
1R21CA227232-01
|
$208,746
|
$208,746
|
TURNBAUGH, PETER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy
|
1R21CA227528-01
|
$176,175
|
$176,175
|
WEICHSELBAUM, RALPH
|
UNIVERSITY OF CHICAGO
|
|
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
|
1R21CA231255-01
|
$189,744
|
|
ROSENBERG, DANIEL
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
|
1R21CA231255-01
|
$189,744
|
$189,744
|
ROSENBERG, DANIEL
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-03
|
$377,438
|
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
|
1R01CA231267-01
|
$460,814
|
|
FEHRENBACHER, JILL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
|
1R01CA231325-01
|
$572,540
|
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
5R01CA219880-02
|
$670,182
|
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression
|
5R01CA220009-02
|
$310,000
|
|
ZANETTI, MAURIZIO
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
(PQ3) Immune epigenetic biomarkers of bladder cancer outcomes
|
5R01CA216265-02
|
$602,394
|
|
CHRISTENSEN, BROCK
|
DARTMOUTH COLLEGE
|
|
(PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer
|
5R01CA206010-03
|
$369,639
|
$369,639
|
CARETHERS, JOHN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
$259,083
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS
|
1R01CA230712-01
|
$633,992
|
|
JENKINS, ROBERT
|
MAYO CLINIC ROCHESTER
|
|
(PQ4) - Tools for simultaneous disruption of multiple epigenetically silenced genes for studying their roles in tumorigenesis using ex vivo human and mouse colon organoid and in vivo mouse models
|
1R01CA230995-01
|
$374,578
|
|
EASWARAN, HARIHARAN
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQ4) - Tools for simultaneous disruption of multiple epigenetically silenced genes for studying their roles in tumorigenesis using ex vivo human and mouse colon organoid and in vivo mouse models
|
1R01CA230995-01
|
$374,578
|
$374,578
|
EASWARAN, HARIHARAN
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
|
1R01CA231112-01
|
$576,627
|
|
CHEN, SIDI
|
YALE UNIVERSITY
|
|
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo
|
1R01CA231253-01
|
$471,700
|
|
WINSLOW, MONTE
|
STANFORD UNIVERSITY
|
|
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma
|
1R01CA219850-01A1
|
$558,022
|
|
DANIAL, NIKA
|
DANA-FARBER CANCER INST
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
3R01CA205967-03S2
|
$230,366
|
$230,366
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
|
5R01CA205967-03
|
$386,588
|
$386,588
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INST
|
|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-03
|
$386,619
|
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
|
1R01CA216101-01A1
|
$670,933
|
|
SHADEL, GERALD
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
|
(PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.
|
5R01CA220004-02
|
$698,964
|
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.
|
5R01CA220004-02
|
$698,964
|
$698,964
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
(PQ6) Roles of circadian rhythms in tumor development
|
1R21CA227379-01
|
$208,800
|
$208,800
|
HONG, CHRISTIAN
|
UNIVERSITY OF CINCINNATI
|
|
(PQ6)Nuclear receptor mechanisms in circadian disruption induced hepatocarcinogenesis
|
1R01CA230848-01
|
$442,560
|
|
FU, LONING
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
|
5R01CA208735-02
|
$730,063
|
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
|
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
|
1R01CA231295-01
|
$481,288
|
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ9) Directed and unbiased studies of synaptic injuries as sequelae of radiotherapy: mapping, sex-dependence, and reversal
|
5R01CA219667-02
|
$523,048
|
|
DUMAN, JOSEPH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ9) A NOVEL MECHANISM OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY AND POTENTIAL TREATMENT
|
5R01CA208765-03
|
$343,846
|
|
YANG, QING
|
UNIVERSITY OF TEXAS MED BR GALVESTON
|
|
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae
|
5R01CA208634-03
|
$560,277
|
|
JURECIC, ROLAND
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer
|
1R01CA230854-01
|
$249,841
|
|
JIN, JIAN
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment
|
5R01CA217934-02
|
$463,899
|
|
ST CLAIR, DARET
|
UNIVERSITY OF KENTUCKY
|
|
(PQB-1) Telomere maintenance defects and thyroid second cancer in childhood cancer survivors
|
5R01CA194473-04
|
$119,807
|
|
GRAMATGES, MARIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQC1) Accelerated biological aging and colon polyp to cancer progression
|
5R01CA194663-04
|
$401,448
|
$401,448
|
GRADY, WILLIAM
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
Total relevant funding to Colon/Rectum for this search: $299,113,530
|